With Bausch $BHC and $TEVA's rebound already playing out, here are six biotech picks for the month of January, below. 1/ $EDIT - the gene editing firm fell only because its value is in the IP and technology and not the revenue at this time. $EDIT, Editas Medicine, Inc. / H1 2/ $CRSP is also down for the same reasons as $EDIT. Now that the biotech sector is fundamentally improving, these stocks will go up, too. Drug firms raised drug prices without government scrutiny. $CELG was bought by $BMY, stiring M&A fever. 3/ $NTLA will post study resultsthat could help the stock continue its move higher. $NTLA, Intellia Therapeutics, Inc. / H1 $BMY is winning back shareholders. You could buy $CELG and get BMY at a discount: $BMY, Bristol-Myers Squibb Company / H1 $BLUE announced a private licensing deal with Inhibrx: $BLUE, bluebird bio, Inc. / H1